Entero Therapeutics to Present Celiac Research at 20th International Celiac Symposium

Entero Therapeutics, Inc. (NASDAQ: ENTO), a clinical-stage biopharmaceutical company focused on gastrointestinal (GI) diseases, has announced that an abstract has been accepted for oral presentation at the 20th International Celiac Disease Symposium (ICDS) 2024. The symposium will be held from September 5-7, 2024, in Sheffield, U.K.

The presentation, titled "A Composite Mucosal Scale for Celiac Disease Encompassing Both Morphology and Inflammation," will be delivered by Jack Syage, Ph.D., President and Chief Scientific Officer of Entero Therapeutics. Dr. Syage expressed enthusiasm about sharing their findings with the celiac disease research community. He emphasized that their new measurement approach represents a significant advancement in monitoring and diagnosing celiac disease, aiming to improve the precision of measuring disease severity and treatment effectiveness.

Latiglutenase, a key development by Entero Therapeutics, is an orally administered mixture of two gluten-specific recombinant proteases. These proteases are minimally systemically absorbed and have shown efficacy in reducing GI symptoms and protecting against intestinal damage in three Phase 2 trials. The U.S. Food and Drug Administration (FDA) has reviewed the Phase 3 clinical development plan for latiglutenase, with trials expected to commence in early 2025.

Celiac disease is a chronic, hereditary autoimmune condition triggered by gluten consumption. It is characterized by damage to the small intestine’s lining, leading to malabsorption, gastrointestinal dysfunction, and significant symptoms. If not properly managed, celiac disease can lead to deteriorating health and increased morbidity and mortality. The disease affects approximately 1% of the global population, with its prevalence on the rise due to better diagnostic tools and awareness.

The International Celiac Disease Symposium is a biennial event organized by the International Society for Study of Celiac Disease (ISSCD). It is the largest global meeting for health professionals, researchers, and scientists dedicated to advancing scientific knowledge, education, and quality of care in celiac disease and gluten-related conditions. The 2024 symposium will take place in Sheffield from September 5-7.

Entero Therapeutics is headquartered in Boca Raton, Florida, and specializes in developing targeted, non-systemic therapies for GI diseases. Besides latiglutenase, the company's development pipeline includes capeserod, a selective 5-HT4 receptor partial agonist for gastroparesis, and adrulipase, a recombinant lipase enzyme aimed at aiding the digestion of fats and nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Overall, Entero Therapeutics is at the forefront of improving treatment options for GI diseases, making significant strides with their innovative therapies. The upcoming presentation at the ICDS 2024 reflects the company's ongoing commitment to advancing the understanding and management of celiac disease.